Repeat Biomarker Status in Breast Resection Specimens With Controlled Cold Ischemic Time. Am J Clin Pathol 2019 Nov 04;152(6):766-774
Date
07/25/2019Pubmed ID
31338514DOI
10.1093/ajcp/aqz105Scopus ID
2-s2.0-85074552661 (requires institutional sign-in at Scopus site) 1 CitationAbstract
OBJECTIVES: Current College of American Pathologists/American Society of Clinical Oncology guidelines recommend cold ischemic time (CIT) of 1 hour or less for breast specimens to preserve biomarker expression, although some publications support an acceptable CIT of 4 hours or less. We retrospectively evaluated changes in estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) from biopsy to resection specimens that were triaged to optimize CIT.
METHODS: We identified breast resection specimens collected after institutional implementation of a triage protocol. Clinicopathologic features were assessed.
RESULTS: In total, 295 excisions had a prior malignant diagnosis, with CIT of 4 hours or less and repeat ER, PR, and/or HER2; 230 (78%) had CIT of 1 hour or less, and 65 (22%) had CIT of more than 1 hour but 4 hours or less. Categorical change was seen in 10 (17.9%) of 56 with repeated ER/PR and 38 (13.3%) of 285 with repeated HER2 (of which five [1.8%] had meaningful change).
CONCLUSIONS: When CIT is optimized, a meaningful change in biomarker expression is infrequent. This study supports that when specimens are appropriately triaged, CIT of 4 hours or less may be acceptable.
Author List
East EG, Roberts E, Zhao L, Jorns JMAuthor
Julie M. Jorns MD Professor in the Pathology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Biomarkers, Tumor
Breast Neoplasms
Cold Ischemia
Female
Humans
Male
Middle Aged
Pathology, Surgical
Specimen Handling
